1. Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

    Submitted by centretek on Sat, 10/15/2022 - 10:30
    Summary
    This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.

  2. Cystic Fibrosis (CF) Foundation Registry

    Submitted by centretek on Sat, 10/15/2022 - 10:30
    Summary
    The goal of the CFF Registry is to develop and maintain a database of CF patients that collects and stores de-identified patient medical information and other related information. This information is used to create CF care guidelines, assist care teams providing care to individuals with CF and guide quality improvement initiatives at care centers. Researchers also use the Patient Registry to study CF treatments and outcomes and to design CF clinical trials.

  3. DCM Precision Medicine Study

    Submitted by centretek on Sat, 10/15/2022 - 10:30
    Summary
    The purpose of this study is to identify gene changes that cause DCM and gene differences that influence the development and severity of DCM. These genetic studies may identify a change in a gene that has already been linked with DCM, a change in a gene not previously associated with DCM, or these studies may identify a gene or genes that affect the development and severity of the DCM. With this knowledge we hope to have a better understanding of how genes and gene changes cause DCM.

  5. A Double-Blind, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR with Placebo in Female Subjects with Stress Urinary Incontinence

    Submitted by centretek on Sat, 10/15/2022 - 10:30
    Summary
    Does sneezing, coughing, laughing, or exertion cause you accidental leaks? Have you had these symptoms for more than 6 months? Are you a woman aged 18 or older? If so, you may be one of millions of women with the condition stress urinary incontinence, or SUI. A clinical research study evaluating whether an investigational product that uses a woman’s own cells may be safe and effective in treating the condition of stress urinary incontinence is being conducted at Inova. This trial is currently enrolling study subjects, and you may be eligible to participate.
Subscribe to